Trials / Completed
CompletedNCT03900572
A Study of Safety and Primary Immunogenicity of 9-valent HPV Recombinant Vaccine
A Randomized, Double-Blind and Placebo-Controlled Phase I Study to Evaluate the Safety and Immunogenicity of a 9-valent Human Papillomavirus (Types 6, 11, 16, 18,31,33,45,52 and 58) Recombinant Vaccine (Pichia Pastoris) in 9 to 45 Year Old Chinese Females
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 90 (actual)
- Sponsor
- Shanghai Zerun Biotechnology Co.,Ltd · Industry
- Sex
- Female
- Age
- 9 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
A randomized, double-blind and placebo-controlled phase I study to evaluate the safety and immunogenicity of a 9-valent Human Papillomavirus (HPV) vaccine, administered intramuscularly according to a 0, 2, 6-month schedule in 9 to 45 years old healthy Chinese females.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | HPV Vaccine | Intramuscular injection, 3 doses |
| DRUG | Placebo | Intramuscular injection, 3 doses |
Timeline
- Start date
- 2019-03-09
- Primary completion
- 2020-04-30
- Completion
- 2020-04-30
- First posted
- 2019-04-03
- Last updated
- 2023-04-13
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03900572. Inclusion in this directory is not an endorsement.